-

Circle Pharma to Present at the Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced that Chief Executive Officer David Earp, JD, Ph.D., will present at the following investor conferences:

Circle Pharma Chief Executive Officer David Earp, JD, Ph.D., to present at the 24th Annual Needham Virtual Healthcare Conference and the Stifel 2025 Virtual Targeted Oncology Forum.

Share
  • 24th Annual Needham Virtual Healthcare Conference
    April 9, 2025
    11:45 a.m. – 12:25 p.m. ET
  • Stifel 2025 Virtual Targeted Oncology Forum
    April 9, 2025
    1:30 p.m. – 1:55 p.m. ET

About Circle Pharma

South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a Cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial for patients with advanced solid tumors.

To learn more about Circle Pharma, please visit www.circlepharma.com.

Contacts

Media Contact:
Roslyn Patterson
Phone: 650.825.4099
Email: roslyn.patterson@circlepharma.com

Industry:

Circle Pharma

Release Versions
English
Hashtags
#BreastCancer
#LungCancer
#Macrocycles
#SCLC
#TNBC

Contacts

Media Contact:
Roslyn Patterson
Phone: 650.825.4099
Email: roslyn.patterson@circlepharma.com

Social Media Profiles
Circle Pharma on LinkedIn
More News From Circle Pharma

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. The poster will present new mechanistic insights into the anti-cancer activity of cyclin A/B RxL inhibitors, including their impact on DNA repair pathways and mitotic progression in E2...

Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced a poster for preclinical data on CID-078, a first-in-class oral macrocycle cyclin A/B RxL inhibitor, will be presented at the San Antonio Breast Cancer Symposium 2024. The event, which runs from December 10-13, brings together global leaders in breast cancer research and treatment. Poster present...

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced that preclinical data from its lead candidate, CID-078, a first-in-class oral macrocycle cyclin A/B RxL inhibitor, has been selected for a late-breaking poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, also known as the Triple Meeting. The sym...
Back to Newsroom